Immunotherapy in Recurrent Ovarian Cancer
Background/Objectives: It remains challenging to treat recurrent ovarian cancer effectively as traditional interventions like chemotherapy and surgery have limited long-term efficacy, highlighting an urgent need for innovative approaches. Immunotherapy offers potential advantages in modulating the i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/168 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589013414838272 |
|---|---|
| author | Keyao Chen Jingjing Wang Meng Yang Shaoqiong Deng Li Sun |
| author_facet | Keyao Chen Jingjing Wang Meng Yang Shaoqiong Deng Li Sun |
| author_sort | Keyao Chen |
| collection | DOAJ |
| description | Background/Objectives: It remains challenging to treat recurrent ovarian cancer effectively as traditional interventions like chemotherapy and surgery have limited long-term efficacy, highlighting an urgent need for innovative approaches. Immunotherapy offers potential advantages in modulating the immune response against tumor cells and has emerged as a promising strategy in ovarian cancer management. This review discusses various immunotherapy modalities, including active and passive immune strategies, for recurrent ovarian cancer. Methods: We systematically reviewed recent immunotherapy advances for recurrent ovarian cancer, including the efficacy and mechanisms of single and dual immune checkpoint inhibitors, checkpoint inhibitor combinations with chemotherapy or radiotherapy, anti-angiogenic agents, PARP inhibitors, antibody–drug conjugates (ADC), tumor vaccines, and adoptive cell therapies (ACT). Additionally, we assessed emerging research on biomarkers predictive of immunotherapy responsiveness in ovarian cancer. Results: The findings indicate that immunotherapy, particularly combinations involving immune checkpoint inhibitors and other agents, demonstrates promising efficacy in recurrent ovarian cancer, with some therapies showing enhanced benefits in specific subtypes. The immune microenvironment in platinum-sensitive and -resistant cases exhibits distinct immunological profiles, influencing therapy outcomes. Several potential biomarkers have been identified, potentially aiding in patient stratification and treatment optimization. Conclusions: Immunotherapy significantly advances recurrent ovarian cancer treatment, with various combinations potentially improving outcomes. Further research on predictive biomarkers and immune microenvironment characteristics is crucial for personalizing immunotherapy approaches and enhancing their efficacy in managing recurrent ovarian cancer. |
| format | Article |
| id | doaj-art-dcc194fa51a54326b66360062250fe82 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-dcc194fa51a54326b66360062250fe822025-01-24T13:24:15ZengMDPI AGBiomedicines2227-90592025-01-0113116810.3390/biomedicines13010168Immunotherapy in Recurrent Ovarian CancerKeyao Chen0Jingjing Wang1Meng Yang2Shaoqiong Deng3Li Sun4Gynecology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, ChinaGynecology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, ChinaGynecology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, ChinaGynecology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, ChinaGynecology Department, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, ChinaBackground/Objectives: It remains challenging to treat recurrent ovarian cancer effectively as traditional interventions like chemotherapy and surgery have limited long-term efficacy, highlighting an urgent need for innovative approaches. Immunotherapy offers potential advantages in modulating the immune response against tumor cells and has emerged as a promising strategy in ovarian cancer management. This review discusses various immunotherapy modalities, including active and passive immune strategies, for recurrent ovarian cancer. Methods: We systematically reviewed recent immunotherapy advances for recurrent ovarian cancer, including the efficacy and mechanisms of single and dual immune checkpoint inhibitors, checkpoint inhibitor combinations with chemotherapy or radiotherapy, anti-angiogenic agents, PARP inhibitors, antibody–drug conjugates (ADC), tumor vaccines, and adoptive cell therapies (ACT). Additionally, we assessed emerging research on biomarkers predictive of immunotherapy responsiveness in ovarian cancer. Results: The findings indicate that immunotherapy, particularly combinations involving immune checkpoint inhibitors and other agents, demonstrates promising efficacy in recurrent ovarian cancer, with some therapies showing enhanced benefits in specific subtypes. The immune microenvironment in platinum-sensitive and -resistant cases exhibits distinct immunological profiles, influencing therapy outcomes. Several potential biomarkers have been identified, potentially aiding in patient stratification and treatment optimization. Conclusions: Immunotherapy significantly advances recurrent ovarian cancer treatment, with various combinations potentially improving outcomes. Further research on predictive biomarkers and immune microenvironment characteristics is crucial for personalizing immunotherapy approaches and enhancing their efficacy in managing recurrent ovarian cancer.https://www.mdpi.com/2227-9059/13/1/168recurrent ovarian cancerimmunotherapyimmune microenvironment |
| spellingShingle | Keyao Chen Jingjing Wang Meng Yang Shaoqiong Deng Li Sun Immunotherapy in Recurrent Ovarian Cancer Biomedicines recurrent ovarian cancer immunotherapy immune microenvironment |
| title | Immunotherapy in Recurrent Ovarian Cancer |
| title_full | Immunotherapy in Recurrent Ovarian Cancer |
| title_fullStr | Immunotherapy in Recurrent Ovarian Cancer |
| title_full_unstemmed | Immunotherapy in Recurrent Ovarian Cancer |
| title_short | Immunotherapy in Recurrent Ovarian Cancer |
| title_sort | immunotherapy in recurrent ovarian cancer |
| topic | recurrent ovarian cancer immunotherapy immune microenvironment |
| url | https://www.mdpi.com/2227-9059/13/1/168 |
| work_keys_str_mv | AT keyaochen immunotherapyinrecurrentovariancancer AT jingjingwang immunotherapyinrecurrentovariancancer AT mengyang immunotherapyinrecurrentovariancancer AT shaoqiongdeng immunotherapyinrecurrentovariancancer AT lisun immunotherapyinrecurrentovariancancer |